Cosmo Pharmaceuticals reported encouraging long-term results for its experimental male hair loss treatment. The treatment showed sustained hair growth and a strong safety profile after one year of clinical use. The company said its topical drug, clascoterone, delivered continued hair regrowth in men with androgenetic alopecia, a common form of male pattern baldness. The findings come from an extension of ...
What does Glenmark Pharmaceuticals’ recent approval from the UK’s MHRA mean for the acne treatment market? In partnership with Cosmo Pharmaceuticals, Glenmark has secured approval to market Winlevi, a new topical solution for acne vulgaris. This opens up exciting opportunities in the dermatology industry, offering a promising treatment option for those struggling with acne. A strategic partnership for market expansion ...